Notizie AIOM – anno XV n. 631

30 Maggio 2017

ASCO and CAP Invite Comment on Focused Update to HER2 Testing Guideline in Breast Cancer

May 25, 2017 - Draft recommendations as part of a focused update to the ASCO/College of American Pathologists (CAP) evidence-based guideline for human epidermal growth factor receptor 2 (HER2) testing in breast cancer are now open for public comment through June 12, 2017. ...
Leggi tutto

30 Maggio 2017

FDA Panel Supports Neratinib Approval for HER2+ Breast Cancer

May 24, 2017 - The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 12-4 recommending approval of neratinib for the extended adjuvant treatment of patients with early stage, HER2-positive breast cancer following postoperative trastuzumab. ODAC based its recommendation ...
Leggi tutto

30 Maggio 2017

FDA Grants Priority Review to KTE-C19 for Non-Hodgkin Lymphoma

May 26, 2017 - The FDA has granted a priority review to axicabtagene ciloleucel (KTE-C19; axi-cel) for transplant-ineligible patients with relapsed or refractory non-Hodgkin lymphoma (NHL), according to Kite Pharma, the developer of the CD19-directed chimeric antigen receptor ...
Leggi tutto

30 Maggio 2017

Follow-up of elderly patients with urogenital cancers: Evaluation of geriatric care needs and related actions

To investigate a comprehensive geriatric assessment (CGA) with subsequent investigation of healthcare patterns in older patients with urological cancers undergoing initial surgery or radiotherapy, to verify the usefulness of the incorporation of geriatric principles in future ...
Leggi tutto

29 Maggio 2017

ODAC Recommends Approval of Epoetin Alfa Biosimilar

May 25, 2017 - The FDA’s Oncologic Drugs Committee voted (ODAC) 14-1 today to recommend approving a biologics license application (BLA) for epoetin hospira, an epoetin alfa biosimilar manufactured by Hospira. The BLA will now go to the FDA for consideration. The agency ...
Leggi tutto

29 Maggio 2017

FDA Approves Ceritinib for Frontline ALK+ NSCLC

May 26, 2017 - The FDA has approved ceritinib for the treatment of patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC), according to Novartis, the manufacturer of the second-generation ALK inhibitor. Patients’ ALK-positive status must be ...
Leggi tutto

29 Maggio 2017

External quality assessment for EGFR mutations in Italy: improvements in performances over the time

External quality assessment (EQA) schemes are essential procedures to assess the quality level of laboratories performing molecular testing of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer. The Italian Association of Medical Oncology (AIOM) ...
Leggi tutto

29 Maggio 2017

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study

Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating ...
Leggi tutto

29 Maggio 2017

26 maggio 2017 – Comunicazione e condivisione della ricerca: le nuove tecnologie e il valore fondante dell’etica

29 Maggio 2017

26 maggio 2017 – Procedure di applicazione Managed Entry Agreement – medicinali Vemurafenib L.648/96 e Vemurafenib in associazione a Cobimetinib

LAVORIAMO CON

News

I dati di follow-up a lungo termine dello studio di fase 3 con mavacamten sottolineano il profilo consolidato di efficacia e sicurezza nei pazienti con cardiomiopatia ipertrofica

BEIGENE ITALIA: ILARIA PIUZZI NUOVO DIRETTORE PUBLIC AFFAIRS, COMUNICAZIONE E PATIENT ADVOCACY

TUMORI: 22 BARCHE A CAPRERA PER IL PROGETTO “PAZIENTI A BORDO”

IN ITALIA 1,7 MILIONI DI PERSONE COLPITE DA MAL DI SCHIENA INFIAMMATORIO

LISTE D’ATTESA, SEBASTIANI (SIR): “PRIMI IMPORTANTI RISULTATI. ORA LO SPECIALISTA REUMATOLOGO”

Alcol, più donne consumatrici e 15% giovani ama il binge drinking

TUMORI: “PER L’84% DEI PAZIENTI MANCA LO PSICONCOLOGO NEL PERCORSO DI CURA”

Notizie AIOM – anno XV n. 631

ASCO and CAP Invite Comment on Focused Update to HER2 Testing Guideline in Breast Cancer

FDA Panel Supports Neratinib Approval for HER2+ Breast Cancer

FDA Grants Priority Review to KTE-C19 for Non-Hodgkin Lymphoma

Follow-up of elderly patients with urogenital cancers: Evaluation of geriatric care needs and related actions

ODAC Recommends Approval of Epoetin Alfa Biosimilar

FDA Approves Ceritinib for Frontline ALK+ NSCLC

External quality assessment for EGFR mutations in Italy: improvements in performances over the time

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study

26 maggio 2017 – Comunicazione e condivisione della ricerca: le nuove tecnologie e il valore fondante dell’etica

26 maggio 2017 – Procedure di applicazione Managed Entry Agreement – medicinali Vemurafenib L.648/96 e Vemurafenib in associazione a Cobimetinib